Effect and safety of tamsulosin, the prostate specific alpha(1)-blocker, in the treatment of BPH (benign prostatic hyperplasia)

被引：2

作者：

Kawabe, K

机构：

[1] Department of Urology, Faculty of Medicine, The University of Tokyo, Tokyo

来源：

AKTUELLE UROLOGIE | 1996年 / 27卷

关键词：

BPH; alpha-blocker; alpha(1a)-receptor-subtype; tamsulosin;

D O I：

10.1055/s-2008-1055642

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Clinical trials of tamsulosin demonstrate that it is an effective treatment modality for the symptoms associated with BPH, and it has practically no effect on blood pressure at a dose of 0.2 mg. This is probably due to its selective affinity for the prostate, which may be due to the strong affinity of tamsulosin for the alpha(1a)-receptor subtype.

引用

页码：25 / 26

页数：2

共 50 条

[41] Management of benign prostate hyperplasia (BPH) by combinatorial approach using alpha-1-adrenergic antagonists and 5-alpha-reductase inhibitors
Zitoun, Osama A.
Farhat, Abdulrahman M. N.
Mohamed, Mohamed A.
Hamad, Mohammad R.
Aramini, Beatrice
Haider, Khawaja Husnain
EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 883
[42] TAMSULOSIN, A SELECTIVE ALPHA(1C)-ADRENOCEPTOR ANTAGONIST - A RANDOMIZED, CONTROLLED TRIAL IN PATIENTS WITH BENIGN PROSTATIC OBSTRUCTION (SYMPTOMATIC BPH)
ABRAMS, P
SCHULMAN, CC
VAAGE, S
ABEL, P
BAXBY, K
BOEMINGHAUS, F
DELAERE, KPJ
DENIS, L
DIJKMAN, GA
HASSELLUND, S
HOHENFELLNER, R
JANKNEGT, RA
KAPPER, BJ
KARTHAUS, HFM
KHOE, GSS
KIL, PJM
KROMANNANDERSEN, B
LELIEFELD, HHJ
LOCK, TMTW
MOHR, M
MOMMSEN, S
OGREID, P
OTTO, RW
PLASMAN, JWMH
PULL, HC
RYTTOV, N
TOLLEY, DA
VENEMA, PL
WYNDAELE, JJ
YPMA, AFGVM
BRITISH JOURNAL OF UROLOGY, 1995, 76 (03): : 325 - 336
[43] Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin
Djavan, Bob
Dianat, Seyed Saeid
Kazzazi, Amir
PATIENT-RELATED OUTCOME MEASURES, 2011, 2 : 71 - 79
[44] Tadalafil versus tamsulosin as combination therapy with 5-alpha reductase inhibitors in benign prostatic hyperplasia, urinary and sexual outcomes
Tawfik, Ahmed
Abo-Elenen, Mohammed
Gaber, Mohammed
El-Abd, Ahmed
Zoeir, Ahmed
Saad, Sayed
Sultan, Intessar
Ghoneim, Ayman
WORLD JOURNAL OF UROLOGY, 2024, 42 (01)
[45] The efficacy of vardenafil and tamsulosin in treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A randomised clinical trial
Zaza, Mohamed Mahmoud
Hussien, Adham Hussien Mohamed
Salem, Tarek Abdel-Majid
Soliman, Mohamed Hassan Ali
JOURNAL OF CLINICAL UROLOGY, 2024,
[46] The impact of adding solifenacin to tamsulosin therapy for treatment of storage lower urinary tract symptoms owing to benign prostatic hyperplasia
Elbadry, Mohamed
Ali, Ahmed Issam
Saleh, Eman
Kamal, Amal
Gabr, Ahmed H.
AFRICAN JOURNAL OF UROLOGY, 2020, 26 (01)
[47] SPECIFIC ANTIGEN PROSTATIC CHANGES DURING TREATMENT WITH FINASTERIDE OR DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA
Arena, F.
MINERVA UROLOGICA E NEFROLOGICA, 2013, 65 (03) : 211 - 216
[48] Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)
Yu, Hong-Jeng
Lin, Alex Tong-Long
Yang, Stephen Shei-Dei
Tsui, Ke-Hung
Wu, Hsi-Chin
Cheng, Chen-Li
Cheng, Hong-Lin
Wu, Tony T.
Chiang, Po-Hui
BJU INTERNATIONAL, 2011, 108 (11) : 1843 - 1848
[49] The impact of adding solifenacin to tamsulosin therapy for treatment of storage lower urinary tract symptoms owing to benign prostatic hyperplasia
Mohamed Elbadry
Ahmed Issam Ali
Eman Saleh
Amal Kamal
Ahmed H. Gabr
African Journal of Urology, 2020, 26
[50] Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia
Rahardjo, Djoko
Soebadi, Doddy M.
Sugandi, Suwandi
Birowo, Ponco
Djati, Wahjoe
Wahyudi, Irfan
INTERNATIONAL JOURNAL OF UROLOGY, 2006, 13 (11) : 1405 - 1409

← 1 2 3 4 5 →